Kintara Therapeutics Files 2024 10-K
Ticker: HURA · Form: 10-K · Filed: Oct 7, 2024 · CIK: 1498382
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financials
TL;DR
Kintara's 2024 10-K is in, check financials and risks.
AI Summary
Kintara Therapeutics, Inc. filed its 10-K for the fiscal year ending June 30, 2024, reporting on its operations and financial condition. The company, formerly known as DelMar Pharmaceuticals, Inc. and Berry Only Inc., is incorporated in Nevada and headquartered in San Diego, California. The filing details its business, risk factors, and financial statements, including information on common stock and preferred stock.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Kintara Therapeutics' financial health and strategic direction for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Kintara Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 0630 — Fiscal Year End (Indicates the end of the reporting period for the 10-K.)
- 20240630 — Fiscal Year End Date (Specific date for the end of the fiscal year.)
- 20241007 — Filing Date (Date the 10-K was submitted to the SEC.)
Key Players & Entities
- Kintara Therapeutics, Inc. (company) — Filer of the 10-K
- DelMar Pharmaceuticals, Inc. (company) — Former company name
- Berry Only Inc. (company) — Former company name
- 20240630 (date) — Fiscal year end
- 20241007 (date) — Filing date
- San Diego, CA (location) — Company headquarters
FAQ
What was Kintara Therapeutics' former company name?
Kintara Therapeutics, Inc. was formerly known as DelMar Pharmaceuticals, Inc. and Berry Only Inc.
What is the fiscal year end date for this 10-K filing?
The fiscal year end date for this 10-K filing is June 30, 2024.
When was this 10-K filed with the SEC?
This 10-K was filed on October 7, 2024.
In which state is Kintara Therapeutics, Inc. incorporated?
Kintara Therapeutics, Inc. is incorporated in Nevada (NV).
What is the business address of Kintara Therapeutics, Inc.?
The business address is 9920 Pacific Heights Blvd, Suite 150, San Diego, CA 92121.
Filing Stats: 4,591 words · 18 min read · ~15 pages · Grade level 14.4 · Accepted 2024-10-07 17:19:00
Key Financial Figures
- $0.1696 — he closing price of our common stock of $0.1696 was approximately $ 1,723,383 . For pur
- $2 million — o run this study will be covered by the $2 million Small Business Innovation Research gran
- $1.25 million — e received in tranches of approximately $1.25 million for the period July 1, 2023, to June 30
- $0.8 million — period July 1, 2023, to June 30, 2024 ($0.8 million received), and approximately $0.75 mill
- $0.75 million — .8 million received), and approximately $0.75 million for the period July 1, 2024, to June 30
- $500 million — ted market opportunity of approximately $500 million for the treatment of CMBC. Cutaneous
Filing Documents
- ktra-20240630.htm (10-K) — 2607KB
- ktra-ex3_24.htm (EX-3.24) — 19KB
- ktra-ex3_25.htm (EX-3.25) — 19KB
- ktra-ex3_26.htm (EX-3.26) — 19KB
- ktra-ex10_32.htm (EX-10.32) — 42KB
- ktra-ex21_1.htm (EX-21.1) — 3KB
- ktra-ex23_1.htm (EX-23.1) — 5KB
- ktra-ex31_1.htm (EX-31.1) — 16KB
- ktra-ex31_2.htm (EX-31.2) — 16KB
- ktra-ex32_1.htm (EX-32.1) — 9KB
- img140589240_0.jpg (GRAPHIC) — 85KB
- img140589240_1.jpg (GRAPHIC) — 81KB
- 0000950170-24-113321.txt ( ) — 10183KB
- ktra-20240630.xsd (EX-101.SCH) — 1593KB
- ktra-20240630_htm.xml (XML) — 1447KB
Business
Business 2 Item 1A
Risk Factors
Risk Factors 17 Item 1B Unresolved Staff Comments 44 Item 1C Cybersecurity 44 Item 2
Properties
Properties 45 Item 3
Legal Proceedings
Legal Proceedings 45 Item 4 Mine Safety Disclosures 45 PART II Item 5 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 46 Item 6 [Reserved] 46 Item 7
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 47 Item 7A
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 53 Item 8
Financial Statements and Supplementary Data
Financial Statements and Supplementary Data 54 Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 80 Item 9A
Controls and Procedures
Controls and Procedures 80 Item 9B Other Information 80 Item 9C Disclosure Regarding Foreign Jurisdictions Preventing Inspections 81 PART III Item 10 Directors, Executive Officers, and Corporate Governance 82 Item 11
Executive Compensation
Executive Compensation 84 Item 12
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 87 Item 13 Certain Relationships and Related Transactions, and Director Independence 88 Item 14 Principal Accountant Fees and Services 90 PART IV Item 15 Exhibits 91 Item 16 Form 10-K Summary 95
Signatures
Signatures 96 i PAR T I
B usiness
Item 1. B usiness. Background Kintara Therapeutics, Inc. ("Kintara" or the "Company") is a clinical stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. We are the parent company of Del Mar Pharmaceuticals (B.C.) Ltd. ("Del Mar (BC)"), a British Columbia, Canada corporation, and Adgero Biopharmaceuticals Holdings, Inc., a Delaware Corporation ("Adgero"). We are also the parent company of Kayak Mergeco, Inc., our wholly owned subsidiary incorporated in the State of Delaware ("Kayak Mergeco") formed to facilitate the proposed merger with TuHURA Biosciences, Inc. ("TuHURA") as described below. In addition, we are also the parent company to 0959454 B.C. Ltd. ("Callco") and 0959456 B.C. Ltd. ("Exchangeco"), which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the reverse acquisition that occurred in 2013. References to "we," "us," and "our" refer to Kintara and our wholly-owned subsidiaries, Del Mar (BC), Adgero, Adgero Bio, Callco, Exchangeco, and Kayak Mergeco. We are dedicated to the development of novel cancer therapies for patients with unmet medical needs. Our mission is to benefit patients by developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, with particular focus on orphan cancer indications. Our lead candidate is REM-001, a late-stage photodynamic therapy ("PDT") for the treatment of cutaneous metastatic breast cancer ("CMBC"). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. Corporate Events On October 31, 2023, we announced preliminary topline results for VAL-083, a DNA-targeting agent intended to treat drug-resistant solid tumors such as glio